The Hormone We Mistook for Fertility
For decades, medicine treated estrogen primarily as a reproductive hormone. New evidence suggests we may have misunderstood what it was doing all along.
Special note: My book The Billion Dollar Blindspot is now available to purchase. Grab your copy and get your bonus chapter here
Key Takeaways
Women spend more than a third of life after menopause.
Estrogen affects far more than reproduction.
New research links longer hormone exposure with lower heart failure risk.
Women’s health is evolving from a reproductive market to a longevity market.
On a summer morning in July 2002, phones began ringing in doctors’ offices across America. Women who had taken hormone therapy for years wanted answers. Should they stop? Had they put themselves at risk? Was the treatment they had trusted suddenly dangerous?
The questions were triggered by findings from the Women’s Health Initiative (WHI), one of the largest studies ever conducted on women’s health.
By evening, television news anchors were warning viewers about hormones. Within weeks, prescriptions were being cancelled. Within months, one of the most common treatments prescribed to midlife women had become something to fear.
The message travelled quickly. Far more quickly than the nuance. What began as a complex scientific discussion about risks, benefits, age, timing, and patient selection was gradually compressed into a much simpler narrative:
Hormones are dangerous.
For many women, that became the only message they ever heard. More than two decades later, we are still living with the consequences. Yet the most important consequence may not be what happened to hormone prescriptions. It may be what the episode revealed about how we think about women’s health.
For much of modern medical history, estrogen was viewed primarily through the lens of reproduction. Its role seemed obvious. It regulated menstrual cycles, supported fertility, enabled pregnancy and prepared the body for childbirth. When reproductive capacity ended, the assumption was often that estrogen’s most important work was largely done.
Women’s health, consciously or unconsciously, became organized around reproduction. It was a reasonable assumption. The question is whether it told the whole story.
But biology has a habit of refusing to fit neatly into our categories. Over time, researchers began discovering that estrogen was doing far more than helping women conceive children. Estrogen receptors were found throughout the body—in the brain, blood vessels, bones, muscles and in the heart.
The hormone that had been largely framed through the lens of fertility appeared to be involved in systems that had little to do with reproduction and everything to do with how the body functions.
Then we learnt that it helped maintain bone density, influenced vascular health, interacted with the cardiovascular system, played a role in cognition and brain health, and affected muscle mass and metabolism.
The reproductive role of estrogen had always been visible. Now what scientists were beginning to discover was everything else.
A new study published this month offers another clue that this broader understanding may be correct1. Researchers analyzed health records from more than 3.7 million postmenopausal women in South Korea and followed them for approximately ten years. The scale alone is remarkable. Over the course of the study, more than 48,000 women were hospitalized for heart failure, giving researchers an unusually large dataset from which to examine patterns. What they found was striking.
Women with longer lifetime exposure to female sex hormones appeared to have a lower risk of heart failure.
Women who experienced menopause earlier appeared to face a higher risk.
Women with shorter reproductive periods also appeared to face a higher risk.
Meanwhile, women who had used oral contraceptives or menopausal hormone therapy appeared to have lower risks of both heart failure and death following heart failure.
One study does not settle a scientific debate. Nor should it. Science advances through accumulation, not headlines. But when viewed alongside a growing body of research, the findings point in a consistent direction.
The effects of estrogen appear to extend well beyond fertility. The hormone may be influencing systems that shape cardiovascular health, resilience, and long-term outcomes throughout a woman’s life.
For most of human history, this question would have mattered far less. Life expectancy was shorter. Many women simply did not live long enough to spend decades beyond menopause. The years after reproduction existed, but they occupied a much smaller portion of life.
That is no longer true. Today, women can expect to spend more than a third of their lives in the postmenopausal phase. Pause on that for a moment. Not a brief chapter between middle age and old age but decades.
For many women, the years after reproduction may last longer than the years before it—a span of life longer than many people once lived altogether. Yet much of modern medicine still reflects assumptions formed in a different era. An era when women simply did not spend thirty, forty, or fifty years beyond menopause.
The demographic reality is changing but the underlying model has not, and that mismatch is becoming harder to ignore. It is beginning to show up everywhere. In cardiovascular disease, osteoporosis, cognitive health, metabolic health, in frailty and mobility, and in the growing realization that longevity looks different in women than it does in men.
The question facing medicine is no longer simply how to support women’s reproductive health. It is now how to support women’s health across the decades that follow reproduction, and the distinction matters. Because once those decades move from the margins to the center of the conversation, entirely new questions begin to emerge—new research priorities, new therapeutic opportunities, new markets and perhaps most importantly, a new understanding of what women’s health actually means.
Whenever our understanding of a problem changes, opportunities emerge. Not because the world changes overnight, but because we begin to see parts of it that were previously hidden.
For decades, women’s health was largely viewed through the lens of reproduction. That framing shaped research agendas, clinical priorities, innovation, and inevitably, it shaped where capital flowed. The result was a healthcare ecosystem that became attuned to fertility, pregnancy, and childbirth while devoting comparatively less attention to the decades that followed.
Yet those decades are no longer a footnote. They are becoming one of the defining health challenges and opportunities of the 21st century. The implications extend far beyond menopause itself. They touch cardiovascular disease, bone health, cognitive decline, metabolic health, mobility and healthy aging.
In other words, some of the largest health challenges facing women later in life may be connected to the very biological systems we once viewed primarily through a reproductive lens.
That realization is beginning to change the conversation. Researchers are asking new questions. Founders are building new companies. Clinicians are revisiting old assumptions, and investors are starting to look more closely at categories that were once dismissed as niche.
What makes this moment particularly interesting is that the opportunity was not created by a scientific breakthrough alone nor by a new technology. It emerged because demographics changed while our assumptions remained the same. Women did not suddenly start aging differently. We simply reached a point where millions of women were spending thirty, forty, and even fifty years beyond reproduction, forcing us to confront questions that had been hiding in plain sight.
That is often how blind spots work. The evidence, need and market is there but what is missing is the framework to see it clearly.
What fascinates me about stories like this is that they are rarely just about science. They are about assumptions; the assumptions we inherit, the assumptions we build systems around, and the assumptions we continue to believe long after the world has changed.
For decades, we organized women’s health around reproduction because that seemed to be the most important chapter of the story.
Today, demographic trends are forcing a different question: What if the decades after reproduction are just as important?
That question sits at the heart of my new book, The Billion Dollar Blindspot. The book explores how outdated assumptions shaped research, innovation, and investment in women’s health and why some of the most important opportunities in healthcare may emerge when those assumptions begin to break down.
I’m grateful that the book recently reached #1 New Release on Amazon in its category, a sign that more readers are beginning to engage with these ideas. Because this conversation is ultimately about much more than menopause, hormones, or even women’s health.
It is about what happens when we finally start looking at the world as it is, rather than as it used to be. If you’d like to explore these ideas more deeply, you can find The Billion Dollar Blind Spot on Amazon.
Disclaimer & Disclosure
This content is for informational and educational purposes only. It does not constitute financial, investment, legal, or medical advice, or an offer to buy or sell any securities. Opinions expressed are those of the author and may not reflect the views of affiliated organisations. Readers should seek professional advice tailored to their individual circumstances before making investment decisions. Investing involves risk, including potential loss of principal. Past performance does not guarantee future results.
Log Young Kim, Jin-Sung Yuk, Byung Gyu Kim, Reproductive history, hormonal exposure, and risk of heart failure in postmenopausal women: a Korean nationwide study, European Heart Journal, 2026;, ehag380, https://doi.org/10.1093/eurheartj/ehag380